Indirect costs of cervical and breast cancers in Spain

Oliva, Juan; Lobo, Félix; López-Bastida, Julio; Zozaya, Néboa; Romay, Rosa

doi:10.1007/s10198-005-0303-4

Cited by 59 publications

(52 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several studies present the estimation of direct and/ or indirect costs associated with CC in different countries [7][8][9][10][11][12]. The experts of the American Cancer Society indicate that production losses due to CC may be more than a half of the total costs associated with the cancer [13].…”

Section: Methodsmentioning

confidence: 99%

Production lost due to cervical cancer in Poland in 2012

Dubas‐Jakóbczyk

Kocot

Seweryn

et al. 2016

Med Pr

View full text Add to dashboard Cite

Background: Poland has one of the highest cervical cancer mortality rates in Europe. It is related to the problem of late diagnosis and low attendance rate in screening programs. The objective of the study has been to assess the annual production loss due to the cervical cancer morbidity and mortality in Poland in 2012. The outcomes have been to provide comprehensive information on cervical cancer's influence on population's ability to work and its overall economic burden for the society. The study has also provided the methodological framework for disease-related production losses in Polish settings. Material and Methods: The human capital method was used. The production losses were calculated in both monetary and quantitative terms (working days lost) due to 4 following reasons: 1) temporary disability to work, 2) permanent disability, 3) informal care, and 4) mortality. Results: Cervical cancer resulted in approx. 702 964 working days lost in 2012 due to absence at work for both patients and care givers and a total number of 957 678 working days lost due to patients' mortality. The total value of production lost was assessed at 111.4 million euros. More than 66% of this value was attributed to women's mortality. Conclusions: The calculation of production lost due to cervical cancer burden provides strong evidence to support adequate health promotion and disease prevention actions. Actions promoting cervical cancer screening should be intensified including workplace health promotion activities. Med Pr 2016;67(3):289-299Key words: screening, cost of illness, indirect costs, cervical neoplasm, gross domestic product (GDP), economic burden Streszczenie Wstęp: Polska ma jeden z najwyższych w Europie wskaźników umieralności kobiet z powodu nowotworu szyjki macicy. Niewiele kobiet uczestniczy w programach przesiewowych, a u wielu choroba jest późno diagnozowana. Celem badania było oszacowanie produkcji utraconej z powodu występowania nowotworu szyjki macicy w Polsce w 2012 r., a tym samym ocena wpływu choroby na zdolność populacji do pracy. Analizę można traktować również jako przykład metodyki szacowania strat produkcyjnych z powodu występo-wania określonej jednostki chorobowej przy wykorzystaniu dostępnych w Polsce danych. Materiał i metody: Wykorzystano metodę kapitału ludzkiego i oszacowano produkcję utraconą z 4 powodów -1) czasowej niezdolności do pracy, 2) trwałej niezdolności do pracy, 3) opieki członków rodziny nad osobą chorą i 4) umieralności -w kategoriach monetarnych i ilościowych (dni utraconej produkcji). Wyniki: Nowotwór szyjki macicy spowodował w 2012 r. utratę 702 964 dni produkcji z powodu chorobowości i 957 678 dni z powodu umieralności. Całkowitą produkcję utraconą oszacowano na 111,4 mln euro, z czego ponad 66% było spowodowanych zgonami osób chorych na nowotwór. Wnioski: Oszacowanie produkcji utraconej z powodu nowotworu szyjki macicy dostarcza silnych argumentów w procesie alokacji zasobów w sektorze zdrowia na rzecz prewencji nowotworów. Należy zintensyfikować również działania z zak...

show abstract

Section: Methodsmentioning

confidence: 99%

Production lost due to cervical cancer in Poland in 2012

Dubas‐Jakóbczyk

Kocot

Seweryn

et al. 2016

Med Pr

View full text Add to dashboard Cite

show abstract

“…Cancer, and indeed any serious illness, can degrade the quality and reduce the quantity of labour available, and this can have both broad macroeconomic implications in terms of reduced GDP growth (Bloom et al, 2011;MayerFoulkes, 2011;Swift, 2011) and firm-level effects including, among other things, productivity loss (Hanly et al, 2012;Nicholson et al, 2006;Oliva et al, 2005). Employers are becoming increasingly aware of adverse illness-related effects which may include a loss of critical skills obtained through years of on-the-job experience, higher employee turnover, and the need to promote employees prematurely to replace more experienced workers (Berger et al, 2001;Bloom et al, 2011;Hytter, 2007).…”

Section: Discussion An Employer's Perspective On the Cost Of Cancer-rmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

“…The consequences of cancer-related mortality are tragic on a personal level for those affected, but beyond this there are also implications for public health, the economy and society in general. This study focuses on one aspect of cancer, namely the costs this disease impose on employees and employers from an economic perspective (Hanley and Sharp, 2012;Oliva et al, 2005).When an employed individual is diagnosed with cancer, a short-or long-term absence from work normally ensues due to treatment, related side effects or rehabilitation (Bradley et al, 2006;Mehnert, 2011;Mehnert et al, 2013;Sharp and Timmons, 2011). A proportion of patients with cancer also leave the workforce permanently either due to retirement or death.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Cancer and productivity loss in the Irish economy: an employer’s perspective

Hanly

Pearce

Sharp

2017

The Irish Journal of Management

View full text Add to dashboard Cite

Cancer and productivity loss in the Irish economy: an employer's perspective INTRODUCTIONCancer is a leading cause of death internationally and is the second leading cause of death in Ireland after cardiovascular diseases, a pattern commonly seen in developed countries (WHO, 2008). Specifically, in Ireland cancer deaths represented 30% of all deaths in 2010 amounting to an average of over 8,000 deaths annually (NCRI, 2013a). The consequences of cancer-related mortality are tragic on a personal level for those affected, but beyond this there are also implications for public health, the economy and society in general. This study focuses on one aspect of cancer, namely the costs this disease impose on employees and employers from an economic perspective (Hanley and Sharp, 2012;Oliva et al., 2005).When an employed individual is diagnosed with cancer, a short-or long-term absence from work normally ensues due to treatment, related side effects or rehabilitation (Bradley et al., 2006;Mehnert, 2011;Mehnert et al., 2013;Sharp and Timmons, 2011). A proportion of patients with cancer also leave the workforce permanently either due to retirement or death. It is the latter of these -specifically cancer-related premature mortality -that constitutes the focus of this study. Premature mortality results in firm turnover which, in turn, constitute direct and indirect economic losses to the employer. The former arise because of the need to fund such things as separation, replacement and training (Tziner and Birati, 1996) and the latter from lost productivity itself. Specifically, the investment that the employer made in the employee is lost if they leave the workforce due to cancer, and this creates a quantifiable cost.A number of distinct models exist for calculating the costs of turnover in the workforce (Cascio, 1991;Karsan, 2007;Tziner and Birati, 1996); however, these tend to follow general accounting approaches rather than applying economic costing techniques. Where economic costing techniques have been applied, the majority of studies have adopted the human capital approach (HCA) to productivity cost estimation, which measures potential output lost due to absenteeism and turnover rather than actual output loss. More recent conceptual developments have Abstract:The extant literature suggests that cancer-related premature mortality costs have increased over time and are projected to increase further. Previous studies have generally employed a societal rather than an employer-based costing framework. A question therefore remains over the magnitude of productivity costs associated with premature death from cancer from an employer perspective. The objective of this study was to measure the productivity costs associated with cancer-related premature mortality in Ireland using the employer-focussed friction-cost approach (FCA). This entailed the application of an involuntary turnover costing framework rarely used in the management literature and represents the first estimate of its kind in Ireland. The all-cancer premature morta...

show abstract

“…Cabe destacar que durante las discusiones se constataron las enormes diferencias teóricas de partida entre ambos enfoques [7][8][9][10] , lo cual conlleva que las estimaciones realizadas para un mismo problema con diferentes enfoques difieran sustancialmente [11][12][13][14] . Esta circunstancia pone de especial relieve que la elección entre una u otra metodología puede condicionar de manera importante los resultados de las EEIS que incorporen los costes asociados a pérdidas laborales.…”

Section: Ventajas Inconvenientesunclassified